帕博利珠单抗联合二甲双胍治疗转移性头颈部癌的 II 期可行性研究
A Phase II Feasibility Study Combining Pembrolizumab and Metformin in Patients with Metastatic Head and Neck Cancer.
二甲双胍联合帕博利珠单抗耐受性良好,仅出现轻度胃肠道不良事件,并展现出有前景的活性,值得在随机试验中进一步研究。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Oral Lachnoanaerobaculum Levels and Survival in Patients With Head and Neck Cancer.
Oral Lachnoanaerobaculum Levels and Survival in Patients With Head and Neck Cancer.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
这项预后研究发现,在接受(化)放疗的 HNSCC 患者中,唾液 Lachnoanaerobaculum spp 丰度较高与更好的肿瘤控制和生存相关。
探究唾液中Lachnoanaerobaculum属细菌丰度与接受(放)化疗的HNSCC患者治疗结局之间的关联,并探索潜在机制。 设计、场所和参与者:本预后研究分析了纳入两项独立前瞻性生物标志物研究(SALIVA和ZissTrans)并接受根治性(放)化疗的HNSCC患者唾液样本。采用16S rRNA基因测序评估口腔微生物组组成;在有数据的患者中通过免疫组织化学评估TIL(肿瘤浸润淋巴细胞)。并使用癌症微生物组图谱和癌症基因组图谱数据进一步验证结果。样本收集时间为2008–2011年(SALIVA)及2017–2022年(ZissTrans),本研究数据分析时间为2024年7月至12月。 暴露因素:根治性(放)化疗。 主要结局和测量指标:主要结局为局部区域无复发生存期(LRFS),次要结局为总生存期(OS)。其他次要分析评估Lachnoanaerobaculum属丰度与TIL水平的关联,以及重度放射性口腔黏膜炎的发生率。
分析纳入92例HNSCC患者(平均[标准差]年龄61.1[7.9]岁;女性15例[16.3%],男性77例[83.7%])。研究发现,Lachnoanaerobaculum属丰度较高与显著改善的LRFS相关(中位69个月 vs. 11个月;风险比[HR]0.50;95% CI:0.29–0.86),也与OS改善相关(中位75个月 vs. 27个月;HR 0.54;95% CI:0.30–0.98)。多变量Cox回归证实这一发现(LRFS:HR 0.50;95% CI:0.25–1.00;OS:HR 0.37;95% CI:0.16–0.85)。76例患者(82.2%)接受TIL评估,结果显示Lachnoanaerobaculum属水平升高与CD4阳性和CD8阳性TIL计数增加相关。其丰度与重度放射性口腔黏膜炎无明显关联。癌症微生物组图谱数据(n=157)显示,肿瘤内Lachnoanaerobaculum属水平较高与OS改善相关(HR 0.62;95% CI:0.39–0.98)。癌症基因组图谱队列的转录组分析进一步支持Lachnoanaerobaculum高表达肿瘤具有免疫活化微环境。 结论与相关性:本预后研究发现,唾液中Lachnoanaerobaculum属丰度较高与接受(放)化疗的HNSCC患者肿瘤控制改善和生存获益相关。这些发现支持进一步研究靶向微生物组干预能否提高HNSCC治疗效果。
The oral microbiome plays a critical role in cancer treatment responses, yet its influence on outcomes in patients with head and neck squamous cell carcinoma (HNSCC) undergoing (chemo)radiotherapy remains poorly understood. Identifying specific microbiome signatures associated with treatment effectiveness could provide novel prognostic biomarkers and therapeutic targets.
To investigate the association between salivary Lachnoanaerobaculum spp abundance and treatment outcomes in patients with HNSCC undergoing (chemo)radiotherapy and to explore potential mechanisms. DESIGN, SETTING, AND PARTICIPANTS: This prognostic study analyzed saliva samples from patients with HNSCC who were enrolled in 2 independent prospective biomarker studies (SALIVA and ZissTrans) and underwent definitive (chemo)radiotherapy. Oral microbiome composition was assessed using 16S rRNA gene sequencing. Tumor-infiltrating lymphocytes (TILs) were evaluated via immunohistochemistry in patients with available data. Findings were further assessed using data from The Cancer Microbiome Atlas and The Cancer Genome Atlas. Sample collection occurred from 2008 to 2011 (SALIVA) and from 2017 to 2022 (ZissTrans), and the data for this study were analyzed from July to December 2024. EXPOSURE: Definitive (chemo)radiotherapy. MAIN OUTCOMES AND MEASURES: The primary outcome was locoregional recurrence-free survival (LRFS) and a secondary outcome was overall survival (OS). Additional secondary analyses evaluated the association between Lachnoanaerobaculum spp levels and TIL levels, and the incidence of severe radiation-induced oral mucositis.
The analysis included 92 patients with HNSCC (mean [SD] age, 61.1 [7.9] years; 15 female [16.3%] 77 male [83.7%] individuals) and found that higher Lachnoanaerobaculum spp abundance was associated with substantially improved LRFS (median, 69 vs 11 months; hazard ratio [HR], 0.50; 95% CI, 0.29-0.86) and OS (median, 75 vs 27 months; HR, 0.54; 95% CI, 0.30-0.98). This finding was confirmed by multivariable Cox regression (LRFS: HR, 0.50; 95% CI, 0.25-1.00; OS: HR, 0.37; 95% CI, 0.16-0.85). TILs were evaluated in 76 patients (82.2%) and showed that increased Lachnoanaerobaculum spp levels were associated with higher CD4-positive and CD8-positive TIL counts. Lachnoanaerobaculum spp abundance showed no meaningful association with severe radiation-induced oral mucositis. Data from The Cancer Microbiome Atlas (n = 157) indicated that higher intratumoral Lachnoanaerobaculum spp levels were associated with improved OS (HR, 0.62; 95% CI, 0.39-0.98). Transcriptomic analyses in The Cancer Genome Atlas cohort further supported an immune-stimulated tumor microenvironment in Lachnoanaerobaculum-high tumors.
This prognostic study found that higher salivary Lachnoanaerobaculum spp abundance was associated with improved tumor control and survival in patients with HNSCC undergoing (chemo)radiotherapy. These findings support further investigation into microbiome-targeted interventions to improve HNSCC treatment effectiveness.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。